The Oncology Institute, Inc.

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.

The Oncology Institute, Inc. trades as TOI on NASDAQ. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $502.73M of revenue and -$60.61M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

The Oncology Institute, Inc. can be compared against peers such as Agilon Health, Inc., Auna S.A., Autolus Therapeutics plc, CeriBell, Inc., Cross Country Healthcare, Inc., Enhabit, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $486.92M, beta of 0.41, and return on equity of +385.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

TOI currently shows total debt of $103.69M and beta of 0.41. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 4 (2026-06-05 00:00:00), 4 (2026-05-22 00:00:00), 4 (2026-05-22 00:00:00), 4 (2026-05-22 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://theoncologyinstitute.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.